Causes of Death in Anticoagulated Patients With Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 68, Issue 23, 2016, Pages 2508-2521

  Gómez Outes, Antonio ^a   Lagunar Ruíz, Julián ^b   Terleira Fernández, Ana Isabel ^b,c   Calvo Rojas, Gonzalo ^d   Suárez Gea, Maria Luisa ^a   Vargas Castrillón, Emilio ^b,c  

^a Parque Empresarial Las Mercedes   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

apixaban; atrial fibrillation; dabigatran; rivaroxaban; stroke; warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

AGE; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENDER; HEART DEATH; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERMANENT ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; FEMALE; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; REGISTER; RETROSPECTIVE STUDY; STROKE; SURVIVAL RATE; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; SURVIVAL RATE; UNITED STATES;

EID: 85002531105     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.944     Document Type: Article

References (42)

1. 1 Fuster, V., Rydén, L.E., Cannom, D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 57 (2011), e101–e198.
2. 2 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
3. 3 Gómez-Outes, A., Suárez-Gea, M.L., Lecumberri, R., et al. Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Eur J Haematol 95 (2015), 389–404.
4. 4 Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
5. 5 Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
6. 6 Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
7. 7 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Controlled Clin Trials 7 (1986), 177–188.
8. 8 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
9. 9 Marijon, E., Le Heuzey, J.Y., Connolly, S., et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 128 (2013), 2192–2201.
10. 10 Hart, R.G., Diener, H.C., Yang, S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43 (2012), 1511–1517.
11. 11 Hohnloser, S.H., Oldgren, J., Yang, S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125 (2012), 669–676.
12. 12 Beasley N, Thompson A. Questions: dabigatran. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee. September 20, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed May 9, 2016.
13. 13 Committee for Medicinal Products for Human Use (CHMP). Pradaxa (dabigatran). Assessment report No.: EMEA/H/C/000829/X/13/G. August 23, 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf. Accessed May 10, 2016.
14. 14 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
15. 15 Pokorney, S.D., Piccini, J.P., Stevens, S.R., et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc, 4, 2016, e002197.
16. 16 Hankey, G.J., Stevens, S.R., Piccini, J.P., et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 45 (2014), 1304–1312.
17. 17 Beasley N, Dunnmon P, Rose M. Xarelto (rivaroxaban). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). September 8, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf. Accessed May 9, 2016.
18. 18 Committee for Medicinal Products for Human Use (CHMP). Xarelto (rivaroxaban). Assessment report No.: EMEA/H/C/000944/II/0012. September 22, 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000944/WC500120735.pdf. Accessed May 10, 2016.
19. 19 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
20. 20 Center for Drug Evaluation and Research. Eliquis (apixaban). Clinical Review Addendum. December 17, 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf. Accessed May 9, 2016.
21. 21 Committee for Medicinal Products for Human Use (CHMP). Eliquis (apixaban). Assessment report No.: EMEA/H/C/002148/X/04/G. September 20, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002148/WC500136575.pdf. Accessed May 10, 2016.
22. 22 Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
23. 23 Giugliano, R.P., Ruff, C.T., Wiviott, S.D., et al. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial. Am J Med 129 (2016), 850–857.
24. 24 Blank M, McDowell TY, Rose M. Savaysa (edoxaban). FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). October 30, 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM420704.pdf. Accessed May 9, 2016.
25. 25 Committee for Medicinal Products for Human Use (CHMP). Lixiana (edoxaban). Assessment report No.: EMEA/H/C/002629/0000. April 23, 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002629/WC500189047.pdf. Accessed May 10, 2016.
26. 26 Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
27. 27 Fox, C.S., Golden, S.H., Anderson, C., et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 132 (2015), 691–718.
28. 28 Gómez-Outes, A., Terleira-Fernández, A.I., Calvo-Rojas, G., et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis, 2013, 2013, 640723.
29. 29 Rossaint, R., Bouillon, B., Cerny, V., et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care, 20, 2016, 100.
30. 30 Steffel, J., Giugliano, R.P., Braunwald, E., et al. Edoxaban versus warfarin in patients at increased risk of falling - a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Circulation, 132 Suppl 3, 2015, A11748.
31. 31 Chai-Adisaksopha, C., Hillis, C., Isayama, T., et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 13 (2015), 2012–2020.
32. 32 Connolly, S.J., Pogue, J., Eikelboom, J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118 (2008), 2029–2037.
33. 33 Van Walraven, C., Jennings, A., Oake, N., et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129 (2006), 1155–1166.
34. 34 Singer, D.E., Hellkamp, A.S., Piccini, J.P., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2, 2013, e000067.
35. 35 Wallentin, L., Yusuf, S., Ezekowitz, M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376 (2010), 975–983.
36. 36 Gómez-Outes, A., Terleira-Fernández, A.I., Calvo-Rojas, G., et al. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol 82 (2016), 633–644.
37. 37 Wang, S.V., Franklin, J.M., Glynn, R.J., et al. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ, 353, 2016, i2607.
38. 38 Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003), 1050–1065.
39. 39 Desmaele, S., Steurbaut, S., Cornu, P., et al. Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?. Eur J Clin Pharmacol 72 (2016), 1125–1134.
40. 40 Tanislav, C., Milde, S., Schwartzkopff, S., et al. Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice. BMC Res Notes, 8, 2015, 262.
41. 41 Blin, P., Dureau-Pournin, C., Lassalle, R., et al. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol 81 (2016), 569–578.
42. 42 Larsen, T.B., Skjøth, F., Nielsen, P.B., et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 353, 2016, i3189.